Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR mutation prevalence and quality of life with first-line erlotinib in UK NSCLC patients
2010-021120-96Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Prevalence of EGFR exon 19 deletion or exon 21 mutation. Started Oct 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-021120-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021120-96.